Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Vomiting

Thromboembolism

Signs and Symptoms, Digestive

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Emetics

Aprepitant

HEC or MEC

Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).

Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.

CV Events in Emetogenic Chemotherapy

Cardiovascular Events in Cancer Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy

GlaxoSmithKline

Nausea

Anti-Inflammatory Agents

Antineoplastic Agents

Reproductive Control Agents

Central Nervous System Stimulants

Dexamethasone

Palonosetron

Cisplatin

Megestrol

Megestrol Acetate

Dexamethasone acetate

Serotonin

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Contraceptive Agents

Contraceptives, Oral

Contraceptives, Oral, Hormonal

Contraceptive Agents, Female

Contraceptive Agents, Hormonal

Palonosetron 2.5mg, Dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, Megestrol acetates 160mg orally every morning on the day of the beginning of chemotherapy for 10 days.

Palonosetron 2.5mg, Dexamethasone12mg on the first day, 8mg on the 2nd-4th day

160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.

5-HT3 receptor antagonist

dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,

dexamethasone

Ning Li

Suxia Luo

To compare the efficacy and safety of megestrol acetate dispersible tablets combined with 5-HT3 receptor antagonist and dexamethasone triple antiemetic regimen and 5-HT3 receptor antagonist and dexamethasone combined antiemetic regimen in the control of CINV induced by hyperemetic chemotherapy.

120 patients with malignant tumors diagnosed by pathology or cytology and treated with highly emetogenic chemotherapy drugs containing cisplatin from September 2018 to December 2019 were selected. The patients were randomly assigned to megestrol group (megestrol acetate dispersible tablets+5-HT3 receptor antagonist+dexamethasone) or control group (5-HT3 receptor antagonist + dexamethasone) at 1:1. The dosage of antiemetic drugs in the control group: 5-HT3 receptor antagonist 2.5mg, dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, all were injected intravenously with 30min before chemotherapy for 5 days. The patients in the megestrol acetate group were given megestrol acetate dispersible tablets on the basis of the control group. 160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days. The main end point was the proportion of control of nausea and vomiting between the two groups during the delayed period (24-120 hours after the beginning of chemotherapy), that is, the proportion of complete remission (no vomiting and no need for rescue treatment) and complete prevention (no nausea and vomiting).The secondary end point was the control ratio of nausea and vomiting in the acute phase (0-24 hours after the beginning of chemotherapy) and the overall phase (0-120 hours after the beginning of chemotherapy); the proportion of patients with grade 3-4 nausea and vomiting during chemotherapy; the adverse reactions related to antiemetic drugs and the score of quality of life of patients in both groups before and after treatment.

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Comparison of the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: a Prospective, Randomized Controlled Phase II Clinical Trial

The main end point was the proportion of control of nausea and vomiting between the two groups during the delayed period chemotherapy

The control ratio of nausea and vomiting in the acute phase and the overall phase

The proportion of patients with grade 3-4 vomiting during chemotherapy

The adverse reactions related to antiemetic drugs of patients in both groups before and after treatment.

The score of quality of life of patients in both groups before and after treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
CV Events in Emetogenic Chemotherapy	NCT01366599	Vomiting Cardiovascular ... Arterial Thromb...	HEC or MEC	-	GlaxoSmithKline
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy	NCT04430361	Tumor Chemotherapy-in...	Megestrol 5-HT3 receptor ... dexamethasone	18 Years - 70 Years	Henan Cancer Hospital

Spots Global Cancer Trial Database for highly emetogenic chemotherapy